The programmed cell death 1 (PD-1) pathway is an important regulator of immune
responses in peripheral tissues, including abnormal situations such as the tumor …

Newly approved systemic treatment options for metastatic urothelial cancer (mUC) have
diversified treatments and improved responses and survival for chemotherapy refractory …

Simple Summary The natural compound sulforaphane is highly popular among tumor
patients, since it is suggested to prevent oncogenesis and cancer progression. However …

Urothelial carcinoma (UC) is the most common histologic type of urinary bladder cancer, and
muscle-invasive UC shows aggressive behaviors. Programmed cell death-1 (PD …

Introduction High recurrence rates, frequent surveillance strategies, and current
multidisciplinary treatment approaches make urothelial carcinoma of bladder (UCB) one of …

Muscle-invasive urothelial carcinoma (MIUC) is the most common type of bladder
malignancy in humans, but also in dogs that represent a naturally occurring model for this …

Background The therapeutic armamentarium of bladder cancer has been recently enriched
with the introduction of new therapies including immune checkpoint inhibitors, receptor …

Systemic therapy is the mainstay of treatment for metastatic urothelial carcinoma (UC).
Responses to first-line platinum-based therapy tend to be short-lived with potential toxicity …

Tumors of the genitourinary tract represent almost 30% of malignancies in the United States.
Prostate cancer accounts for majority of cases followed by urothelial, kidney, and testicular …

Overview Petros Grivas, MD, PhD is a board-certified Medical Oncologist at Seattle Cancer
Care Alliance, WA, USA. He also serves as Clinical Director of the University of Washington …